FDA Validates Urcosimod Phase 3 Path for Neuropathic Corneal Pain, Eyes Single-Trial Registration

summarizeSummary

OKYO Pharma received positive FDA feedback on its Type D meeting for urcosimod, validating its regulatory and clinical path forward into a global Phase 3 pivotal trial for neuropathic corneal pain, with potential for a single-trial registration.

check_boxKey Events · Product Development and Regulatory · OKYO

• FDA Validates Phase 3 Design

  The FDA provided positive feedback on the Type D meeting for urcosimod, validating the clinical path forward for neuropathic corneal pain (NCP).

• Accelerated Clinical Pathway

  The FDA's alignment supports advancement into a global Phase 3 pivotal trial (NEPTUNE) and a potential single-trial registration strategy, de-risking the development program.

• Breakthrough Therapy Designation Planned

  The company plans to seek FDA Breakthrough Therapy Designation (BTD) for urcosimod, which could further accelerate its development and review.

• Addressing Unmet Medical Need

  Urcosimod targets neuropathic corneal pain, a debilitating condition with no currently FDA-approved therapies, and already holds Fast Track designation.

auto_awesomeAnalysis · OKYO · Life Sciences

The FDA's positive feedback on the Type D meeting significantly de-risks OKYO Pharma's lead drug candidate, urcosimod, for neuropathic corneal pain. The alignment on a single-dose Phase 3 study design and the potential for a single-trial registration pathway could significantly accelerate the drug's path to market. This is a critical step for a company targeting an unmet medical need with no approved therapies. The company also plans to seek Breakthrough Therapy Designation, which could further expedite development and review.